Drugs / Sulopenem
Sulopenem
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04700787 | Apr 2021 → Mar 2022 | acute pyelonephritis, infectious peritonitis | Iterum Therapeutics, International Limited | Withdrawn | No outcome recorded |
| Phase 1 | NCT00759564 | Nov 2008 → Mar 2010 | pneumonia | Pfizer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00797108 | Jan → Jun 2009 | bacterial pneumonia | Pfizer | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT03357614 | Sep 2018 → Dec 2019 | urinary tract infection | Iterum Therapeutics, International Limited | Completed | No outcome recorded |
| Phase 3 | NCT03358576 | Sep 2018 → Oct 2019 | intestinal infectious disease | Iterum Therapeutics, International Limited | Completed | No outcome recorded |
| Phase 3 | NCT03354598 | Aug 2018 → Jan 2020 | urinary tract infection | Iterum Therapeutics, International Limited | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-01-05 | Pfizer | Iterum Announces Sulopenem in Development for Treatment of Gram-Negative, Multi-drug Resistant Infections pfizer.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sulopenem | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03358576 ↗ |
| Known as | CP-70,429 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00759564 ↗ |
| Known as | CP-70,429 - sulopenem | “CP-70,429 - sulopenem” NCT00759564 ↗ |
| Modality | Small molecule | — CHEMBL1908305 ↗ |
| Route | Intravenous | “800 mg given as a 1.5 hour intravenous infusion” NCT00759564 ↗ |